Patient need
Autoimmune diseases are driven by complex, interconnected immune pathways involving multiple cell types, yet current treatments often rely on broad immunosuppression or highly specific biologics targeting individual immune cells or inflammatory mediators. There is a significant unmet need for oral therapies that effectively inhibit disease biology further upstream, intervening at the level of innate immune sensing before multiple inflammatory responses across multiple immune cell types are triggered.
Target biology
SLC15A4::TASL represents a promising target at the intersection of innate immune sensing and autoimmune inflammation. Within endolysosomes, SLC15A4 recruits TASL, an essential adaptor that connects the nucleic acid-sensing receptors TLR7, TLR8, and TLR9 to IRF5 activation, a mechanism discovered at our co-founder’s lab. This signalling pathway contributes to the production of type I interferons, inflammatory cytokines, and autoantibodies, all of which play important roles in autoimmune disease.
Our approach
Solgate is developing first-in-class oral small molecules designed to disrupt the interaction between SLC15A4 and TASL. By targeting a shared signalling step downstream of multiple disease drivers, our approach aims to suppress autoimmune inflammation, without depleting immune cell populations or limiting the modality to a single cell type. This offers a differentiated strategy with the potential for broader pathway modulation than individual receptor blockade by biologics, while providing a more targeted alternative to broad immunosuppression.
Towards the clinic
Solgate has nominated development candidates, supported by efficacy and tolerability data. The SLC15A4::TASL pathway offers therapeutic potential across several diseases characterized by dysregulated innate immune signalling and chronic inflammation. Strong biological evidence supports its relevance in systemic lupus erythematosus, lupus nephritis, cutaneous lupus, Sjögren’s disease, dermatomyositis, systemic sclerosis, rheumatoid arthritis, and several rare autoimmune disorders. Additional data supporting the target’s relevance in dermatology and gastroenterology further broaden the potential therapeutic opportunity.
References
SLC15A4::TASL mechanism
Heinz LX et al. Nature (2020). TASL is the SLC15A4-associated adaptor for IRF5 activation by TLR7-9. Read publication
Drobek A et al. Nature Communications (2025). The TLR7/9 adaptors TASL and TASL2 mediate IRF5-dependent antiviral responses and autoimmunity in mouse. Read publication
